Coping with Information Loss and the Use of Auxiliary Sources of Data: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions

References

• Akacha, M., Branson, J., Bretz, F., Dharan, B., Gallo, P., Gathmann, I., Hemmings, R., Jones, J., Xi, D., and Zuber, E. (2020), “Challenges in Assessing the Impact of the COVID-19 Pandemic on the Integrity and Interpretability of Clinical Trials,” Statistics in Biopharmaceutical Research, 12, 419–426. DOI: 10.1080/19466315.2020.1788984.
   PubMed Web of Science ®Google Scholar
• Albertus, M. (2022), “Asymptotic Z and Chi-Squared Tests with Auxiliary Information,” Metrika, 85, 859–883. DOI: 10.1007/s00184-021-00853-y.
   Web of Science ®Google Scholar
• Austin, P. C., and Mamdani, M. M. (2006), “A Comparison of Propensity Score Methods: A Case-Study Estimating the Effectiveness of post-AMI Statin Use,” Statistics in Medicine, 25, 2084–2106. DOI: 10.1002/sim.2328.
   PubMed Web of Science ®Google Scholar
• Azizi, Z., Zheng, M., Mosquera, L., Pilote, L., and El Emam, K. (2021), “Can Synthetic Data be a Proxy for Real Clinical Trial Data? A Validation Study,” BMJ Open, 11, e043497. DOI: 10.1136/bmjopen-2020-043497.
   PubMed Web of Science ®Google Scholar
• Bang, H., and Robins, J. M. (2005), “Doubly Robust Estimation in Missing Data and Causal Inference Models,” Biometrics, 61, 962–973. DOI: 10.1111/j.1541-0420.2005.00377.x.
   PubMed Web of Science ®Google Scholar
• Benkeser, D., Díaz, I., Luedtke, A., Segal, J., Scharfstein, D., and Rosenblum, M. (2021), “Improving Precision and Power in Randomized Trials for Covid-19 Treatments Using Covariate Adjustment, For Binary, Ordinal, and Time-to-Event Outcomes,” Biometrics, 77, 1467–1481. DOI: 10.1111/biom.13377.
   PubMed Web of Science ®Google Scholar
• Burger, H. U., Gerlinger, C., Harbron, C., Koch, A., Posch, M., Rochon, J., and Schiel, A. (2021), “The Use of External Controls: To What Extent Can it Currently Be Recommended?” Pharmaceutical Statistics, 20, 1002–1016. DOI: 10.1002/pst.2120.
   PubMed Web of Science ®Google Scholar
• Chen, M.-H., and Ibrahim, J. G. (2006), “The Relationship between the Power Prior and Hierarchical Models,” Bayesian Analysis, 1, 551–574. DOI: 10.1214/06-BA118.
   Web of Science ®Google Scholar
• Dmitriev, Y., Tarassenko, P., and Ustinov, Y. (2014), “On Estimation of Linear Functional by Utilizing a Prior Guess,” in Information Technologies and Mathematical Modelling, eds. A. Dudin, A. Nazarov, R. Yakupov, and A. Gortsev, pp. 82–90, Cham: Springer.
   Google Scholar
• Duan, Y., Ye, K., and Smith, E. P. (2006), “Evaluating Water Quality Using Power Priors to Incorporate Historical Information,” Environmetrics, 17, 95–106. DOI: 10.1002/env.752.
   Web of Science ®Google Scholar
• Engel, B., and Walstra, P. (1991), “Increasing Precision or Reducing Expense in Regression Experiments by Using Information from a Concomitant Variable,” Biometrics, 47, 13–20. DOI: 10.2307/2532491.
   Web of Science ®Google Scholar
• Epstein, L. H., Schechtman, K. B., Kilanowski, C., Ramel, M., Moursi, N. A., Quattrin, T., Cook, S. R., Eneli, I. U., Pratt, C., Geller, N., et al. (2021), “Implementing Family-based Behavioral Treatment in the Pediatric Primary Care Setting: Design of the PLAN Study,” Contemporary Clinical Trials, 109, 106497. DOI: 10.1016/j.cct.2021.106497.
   PubMed Web of Science ®Google Scholar
• Fogel, D. B. (2018), “Factors Associated with Clinical Trials that Fail and Opportunities for Improving the Likelihood of Success: A Review,” Contemporary Clinical Trials Communications, 11, 156–164. DOI: 10.1016/j.conctc.2018.08.001.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (2010), “Guidance for Industry and FDA Staff: Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials,” available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-use-bayesian-statistics-medical-device-clinical-trials. Accessed: 10.12.2021.
   Google Scholar
• Gabrielsson, J., and Weiner, D. (2007), Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications (4th ed.), Boca Raton, FL: Taylor & Francis.
   Google Scholar
• Galbraith, S., and Marschner, I. C. (2003), “Interim Analysis of Continuous Long-Term Endpoints in Clinical Trials with Longitudinal Outcomes,” Statistics in Medicine, 22, 1787–1805. DOI: 10.1002/sim.1311.
   PubMed Web of Science ®Google Scholar
• Garthwaite, P. H., Kadane, J. B., and O’Hagan, A. (2005), “Statistical Methods for Eliciting Probability Distributions,” Journal of the American Statistical Association, 100, 680–701. DOI: 10.1198/016214505000000105.
   Web of Science ®Google Scholar
• Gravestock, I., Held, L., and On behalf of the COMBACTE-Net consortium. (2017), “Adaptive Power Priors with Empirical Bayes for Clinical Trials,” Pharmaceutical Statistics, 16, 349–360. DOI: 10.1002/pst.1814.
   PubMed Web of Science ®Google Scholar
• Hawila, N., and Berg, A. (2021), “Assessing the Impact of COVID-19 on Registered Interventional Clinical Trials,” Clinical and Translational Science, 14, 1147–1154. DOI: 10.1111/cts.13034.
   PubMed Web of Science ®Google Scholar
• Higgins, J. P., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., and Welch, V. A. (2021), “Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated february 2021),” available at https://www.training.cochrane.org/handbook. Accessed: 28.02.2022.
   Google Scholar
• Hobbs, B. P., Carlin, B. P., Mandrekar, S. J., and Sargent, D. J. (2011), “Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials,” Biometrics, 67, 1047–1056. DOI: 10.1111/j.1541-0420.2011.01564.x.
   PubMed Web of Science ®Google Scholar
• Hobbs, B. P., Sargent, D. J., and Carlin, B. P. (2012), “Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models,” Bayesian Analysis, 7, 639–674. DOI: 10.1214/12-BA722.
   PubMed Web of Science ®Google Scholar
• Hua, E., Janocha, R., Severin, T., Wei, J., and Vandemeulebroecke, M. (2022), “A Phase 3 Trial Analysis Proposal for Mitigating the Impact of the COVID-19 Pandemic,” Statistics in Biopharmaceutical Research, 14, 80–86. DOI: 10.1080/19466315.2021.1905056.
   Web of Science ®Google Scholar
• Ibrahim, J., Chen, M. H., Gwon, Y., and Chen, F. (2015), “The Power Prior: Theory and Applications,” Statistics in Medicine, 34, 3724–3749. DOI: 10.1002/sim.6728.
   PubMed Web of Science ®Google Scholar
• Ibrahim, J. G., and Chen, M.-H. (2000), “Power Prior Distributions for Regression Models,” Statistical Science, 15, 46–60. DOI: 10.1214/ss/1009212673.
   Web of Science ®Google Scholar
• International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (2019), “ICH Harmonised Guideline E9 (R1): Estimands and Sensitivity Analysis in Clinical Trials,” available at https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf. Accessed: 28.02.2022.
   Google Scholar
• James, S., Harbron, C., Branson, J., and Sundler, M. (2021), “Synthetic Data Use: Exploring Use Cases to Optimise Data Utility,” Discover Artificial Intelligence, 1, 1–13. DOI: 10.1007/s44163-021-00016-y.
   Google Scholar
• Kass, R. E., and Raftery, A. E. (1995), “Bayes Factors,” Journal of the American Statistical Association, 90, 773–795. DOI: 10.1080/01621459.1995.10476572.
   Web of Science ®Google Scholar
• Kopp-Schneider, A., Calderazzo, S., and Wiesenfarth, M. (2020), “Power Gains by Using External Information in Clinical Trials are Typically not Possible When Requiring Strict Type I Error Control,” Biometrical Journal, 62, 361–374. DOI: 10.1002/bimj.201800395.
   PubMed Web of Science ®Google Scholar
• Kunz, C. U., Jörgens, S., Bretz, F., Stallard, N., Van Lancker, k., Xi, D., Zohar, S., Gerlinger, C., and Friede, T. (2020), “Clinical Trials Impacted by the COVID-19 Pandemic: Adaptive Designs to the Rescue?” Statistics in Biopharmaceutical Research, 12, 461–477. DOI: 10.1080/19466315.2020.1799857.
   PubMed Web of Science ®Google Scholar
• Lancker, K. V., Tarima, S., Bartlett, J., Bauer, M., Bharani-Dharan, B., Bretz, F., Flournoy, N., Michiels, H., Parra, C. O., Rosenberger, J. L., and Cro, S. (2023), “Rejoinder: Estimands and their Estimators for Clinical Trials Impacted by the Covid-19 Pandemic: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions,” Statistics in Biopharmaceutical Research, 15, 119–124. DOI: 10.1080/19466315.2022.2162958.
   Web of Science ®Google Scholar
• Ledford, H. (2020), “Coronavirus Shuts Down Trials of Drugs for Multiple Other Diseases,” Nature, 580, 15–17. DOI: 10.1038/d41586-020-00889-6.
   PubMed Web of Science ®Google Scholar
• Lunn, D., Barrett, J., Sweeting, M., and Thompson, S. (2013), “Fully Bayesian Hierarchical Modelling in Two Stages, with Application to Meta-Analysis,” Journal of the Royal Statistical Society, Series C, 62, 551–572. DOI: 10.1111/rssc.12007.
   Web of Science ®Google Scholar
• Marschner, I. C., and Becker, S. L. (2001), “Interim Monitoring of Clinical Trials based on Long-Term Binary Endpoints,” Statistics in Medicine, 20, 177–192. DOI: 10.1002/1097-0258(20010130)20:2<177::AID-SIM653>3.0.CO;2-K.
   PubMed Web of Science ®Google Scholar
• Neuenschwander, B., Branson, M., and Spiegelhalter, D. J. (2009), “A Note on the Power Prior,” Statistics in Medicine, 28, 3562–3566. DOI: 10.1002/sim.3722.
   PubMed Web of Science ®Google Scholar
• Neuenschwander, B., Capkun-Niggli, G., Branson, M., and Spiegelhalter, D. J. (2010), “Summarizing Historical Information on Controls in Clinical Trials,” Clinical Trials, 7, 5–18. DOI: 10.1177/1740774509356002.
   PubMed Web of Science ®Google Scholar
• Neuenschwander, B., Roychoudhury, S., and Schmidli, H. (2016), “On the Use of Co-data in Clinical Trials,” Statistics in Biopharmaceutical Research, 8, 345–354. DOI: 10.1080/19466315.2016.1174149.
   Web of Science ®Google Scholar
• Neuenschwander, B., and Schmidli, H. (2020), “Use of Historical Data,” in Bayesian Methods in Pharmaceutical Research, eds. E. Lesaffre, G. Baio, and B. Boulanger, pp. 111–137, Boca Raton, FL: Chapman and Hall/CRC.
   Google Scholar
• Nicholas, R., Straube, S., Schmidli, H., Schneider, S., and Friede, T. (2011), “Trends in Annualized Relapse Rates in Relapsing–Remitting Multiple Sclerosis and Consequences for Clinical Trial Design,” Multiple Sclerosis Journal, 17, 1211–1217. DOI: 10.1177/1352458511406309.
   PubMed Web of Science ®Google Scholar
• O’Hagan, A., Buck, C. E., Daneshkhah, A., Eiser, J. R., Garthwaite, P. H., Jenkinson, D. J., Oakley, J. E., and Rakow, T. (2006), Uncertain Judgements: Eliciting Experts’ Probabilities, Chichester: Wiley.
   Google Scholar
• Ollier, A., Morita, S., Ursino, M., and Zohar, S. (2020), “An Adaptive Power Prior for Sequential Clinical Trials–Application to Bridging Studies,” Statistical Methods in Medical Research, 29, 2282–2294. DOI: 10.1177/0962280219886609.
   PubMed Web of Science ®Google Scholar
• Ollier, A., Zohar, S., Morita, S., and Ursino, M. (2021), “Estimating Similarity of Dose–Response Relationships in Phase I Clinical Trials–Case Study in Bridging Data Package,” International Journal of Environmental Research and Public Health, 18, 1639. DOI: 10.3390/ijerph18041639.
   PubMed Web of Science ®Google Scholar
• Rosenbaum, P. R., Rosenbaum, P., and Briskman  (2010), Design of Observational Studies (Vol. 10), New York: Springer.
   Google Scholar
• Rosenblum, M., Qian, T., Du, Y., and Qiu, H. (2015), “Adaptive Enrichment Designs for Randomized Trials with Delayed Endpoints, Using Locally Efficient Estimators to Improve Precision,” Johns Hopkins University, Department of Biostatistics Working Papers. Working paper 275. Available at https://biostats.bepress.com/jhubiostat/paper275.
   Google Scholar
• Röver, C., Bender, R., Dias, S., Schmid, C. H., Schmidli, H., Sturtz, S., Weber, S., and Friede, T. (2021), “On Weakly Informative Prior Distributions for the Heterogeneity Parameter in Bayesian Random-Effects Meta-Analysis,” Research Synthesis Methods, 12, 448–474. DOI: 10.1002/jrsm.1475.
   PubMed Web of Science ®Google Scholar
• Rowland, M., Peck, C., and Tucker, G. (2011), “Physiologically-based Pharmacokinetics in Drug Development and Regulatory Science,” Annual Review of Pharmacology and Toxicology, 51, 45–73. DOI: 10.1146/annurev-pharmtox-010510-100540.
   PubMed Web of Science ®Google Scholar
• Schmidli, H., Gsteiger, S., Roychoudhury, S., O’Hagan, A., Spiegelhalter, D., and Neuenschwander, B. (2014), “Robust Meta-Analytic-Predictive Priors in Clinical Trials with Historical Control Information,” Biometrics, 70, 1023–1032. DOI: 10.1111/biom.12242.
   PubMed Web of Science ®Google Scholar
• Stallard, N. (2010), “A Confirmatory Seamless Phase II/III Clinical Trial Design Incorporating Short-Term Endpoint Information,” Statistics in Medicine, 29, 959–971. DOI: 10.1002/sim.3863.
   PubMed Web of Science ®Google Scholar
• Takeda, K., and Morita, S. (2018), “Bayesian Dose-Finding Phase I Trial Design Incorporating Historical Data from a Preceding Trial,” Pharmaceutical Statistics, 17, 372–382. DOI: 10.1002/pst.1850.
   PubMed Web of Science ®Google Scholar
• Tarima, S., and Pavlov, D. (2006), “Using Auxiliary Information in Statistical Function Estimation,” ESAIM: Probability and Statistics, 10, 11–23. DOI: 10.1051/ps:2005019.
   Google Scholar
• Tarima, S., Slavova, S., Fritsch, T., and Hall, L. (2007), “Probability Estimation When Some Observations are Grouped,” Statistics in Medicine 26, 1745–1761. DOI: 10.1002/sim.2810.
   PubMed Web of Science ®Google Scholar
• Tarima, S., Tuyishimire, B., Sparapani, R., Rein, L., and Meurer, J. (2020), “Estimation Combining Unbiased and Possibly Biased Estimators,” Journal of Statistical Theory and Practice, 14, 1–20. DOI: 10.1007/s42519-020-0083-2.
   Web of Science ®Google Scholar
• van Dorn, A. (2020), “COVID-19 and Readjusting Clinical Trials,” Lancet, 396, 523–524. DOI: 10.1016/S0140-6736(20)31787-6.
   PubMed Web of Science ®Google Scholar
• Van Lancker, K., Tarima, S., Bartlett, J., Bauer, M., Bharani-Dharan, B., Bretz, F., Flournoy, N., Michiels, H., Parra, C. O., Rosenberger, J. L., and Cro, S. (2022), “Estimands and their Estimators for Clinical Trials Impacted by the Covid-19 Pandemic: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions,” Statistics in Biopharmaceutical Research, 15, 94–111. DOI: 10.1080/19466315.2022.2094459.
   Google Scholar
• Van Lancker, K., Vandebosch, A., and Vansteelandt, S. (2020), “Improving Interim Decisions in Randomized Trials by Exploiting Information on Short-Term Endpoints and Prognostic Baseline Covariates,” Pharmaceutical Statistics, 19, 583–601. DOI: 10.1002/pst.2014.
   PubMed Web of Science ®Google Scholar
• Viele, K., Berry, S., Neuenschwander, B., Amzal, B., Chen, F., Enas, N., Hobbs, B., Ibrahim, J. G., Kinnersley, N., Lindborg, S., Micallef, S., Roychoudhury, S., and Thompson, L. (2014), “Use of Historical Control Data for Assessing Treatment Effects in Clinical Trials,” Pharmaceutical Statistics, 13, 41–54. DOI: 10.1002/pst.1589.
   PubMed Web of Science ®Google Scholar
• Zenkova, Z., and Krainova, E. (2017), “Estimating the Net Premium using Additional Information about a Quantile of the Cumulative Distribution Function,” Business Informatics, 42, 55–63. DOI: 10.17323/1998-0663.2017.4.55.63.
   Google Scholar